What Is Pinealon? Definition and What Research Reports

Plain definition

Pinealon is the name given to a very short synthetic peptide that has been used as an experimental compound in laboratory and animal research, mostly by research groups in Russia and neighbouring countries. In everyday language, it is a small chain of amino acids made in a laboratory and given a brand-style research name, rather than a natural hormone, a vitamin or an approved drug. Nearly everything published about it comes from cell cultures and rodent experiments, not from large human trials, and it is not an approved medicine in the United States, the European Union or the United Kingdom. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any substance you are considering.

What pinealon is in biochemical terms

In biochemical shorthand, pinealon is usually described as a tripeptide — a chain of only three amino acid residues — written as Glu-Asp-Arg and abbreviated EDR using single-letter amino acid codes. Three residues is extremely small by peptide standards; for comparison, insulin has 51 residues and semaglutide has 31. Molecules of this size are not large enough to fold into the complex three-dimensional shapes that classical receptor-binding hormones use, which is one reason the proposed mechanisms for this class are usually framed in terms of interactions with nucleic acids and regulation of gene expression rather than classical receptor agonism.

The "short regulatory peptide" family

Pinealon sits inside a wider group of di-, tri- and tetrapeptides that were developed alongside organ-derived peptide preparations such as Cortexin and Epithalamin. Papers in this tradition typically pair a synthetic short peptide with an older organ extract and compare the two in the same animal model — for example, one 2014 report examined Cortexin and pinealon together in a model of acute hypoxic hypoxia in old rats (PMID 25051764), and a 2015 report examined the same pairing in 18-month-old rats exposed to hypoxia and hypothermia (PMID 28509493). The framing in this literature is peptide bioregulation: the idea that very short peptides act as signalling cues that influence transcription in specific tissues.

How the term is used in peptide research

Three uses of the word are common in the published record:

• As a named test compound. Study titles frequently name pinealon directly as the substance administered in a model, as in the 2012 report on prenatal hyperhomocysteinemia in rat offspring (PMID 22567179).
• As a member of a peptide class. Reviews and discussion sections use "pinealon" as one example of short regulatory peptides, alongside other named members of the same family.
• As a synonym for the sequence EDR. Some papers use the trade-style name and others use the three-letter sequence, which means database searches for one term can miss results indexed under the other.

Where the term is misused

Several confusions recur in non-scientific writing:

• Confusing pinealon with melatonin or with the pineal gland itself. The name evokes the pineal gland, but pinealon is a synthetic peptide, not a pineal hormone and not a melatonin analogue. Naming resemblance is not pharmacological resemblance.
• Confusing it with Cortexin or Epithalon. These are separate preparations. Where Cortexin appears in the same paper, it is a comparator or co-treatment, not the same substance (PMID 25051764).
• Treating rodent and cell-culture findings as human findings. The published work summarised below was conducted in cultured cells and in rats; the literature does not establish the same outcomes in people.
• Describing it as an approved "nootropic" drug. No regulatory agency in the US, EU or UK has approved pinealon as a medicine; material sold under the name in research-supply channels is typically labelled research-use-only, which is a supply designation, not a statement of safety or efficacy.

What the published literature reports

Cell viability and free radicals

A 2011 paper in Rejuvenation Research reported that pinealon increased cell viability, with the authors attributing the change to suppression of free radical levels and activation of proliferative processes (PMID 21978084). The study was a laboratory investigation rather than a clinical trial, so the reported effect describes what happened to cells under experimental conditions and does not describe an outcome in humans.

Hypoxia and hypothermia in aged rats

Researchers examined pinealon alongside Cortexin in 18-month-old rats subjected to hypoxia and hypothermia, and reported effects on behavioural measures and neurochemical processes in that model (PMID 28509493). A related 2014 report used a model of acute hypoxic hypoxia in old rats and examined serum cytokine content together with caspase-3 activity in brain tissue, describing regulation of those markers with Cortexin and pinealon (PMID 25051764). Caspase-3 is an enzyme commonly measured as an index of apoptosis, and cytokines are signalling proteins often measured as an index of inflammatory activity; both are surrogate laboratory markers rather than clinical endpoints.

Prenatal hyperhomocysteinemia model

A 2012 paper in the International Journal of Clinical and Experimental Medicine reported that pinealon protected rat offspring in a model of prenatal hyperhomocysteinemia — an experimental setting in which elevated maternal homocysteine is used to stress the developing nervous system (PMID 22567179). As with the other entries, the study was preclinical and its conclusions apply to the animal model tested.

Summary table

Safety and Adverse Events: What Studies Report

The verified literature indexed for this entry consists of preclinical reports whose stated aims were efficacy-type outcomes — cell viability, behaviour, cytokines, caspase-3 activity and protection in a developmental model (PMID 21978084, PMID 28509493). None of them is a human safety trial, and no controlled human tolerability data for pinealon appear in this set. The absence of reported adverse events in a small preclinical literature is not evidence of safety; it reflects the fact that the question was not the subject of the studies. Readers evaluating any unapproved compound should note that purity, identity and contamination are additional unknowns outside of regulated manufacturing.

Related terms

• EDR (Glu-Asp-Arg) — the sequence notation frequently used in place of the name.
• Short regulatory peptides / peptide bioregulators — the class label used across this research tradition.
• Cortexin — a separate peptide preparation used as a comparator or co-treatment in two of the cited rat studies (PMID 25051764).
• Hypoxic hypoxia — an experimental oxygen-deprivation model used in the aged-rat studies.
• Caspase-3 — an apoptosis-related enzyme measured as a biochemical marker.
• Hyperhomocysteinemia — elevated homocysteine, used experimentally as a prenatal stressor.

How to read this literature critically

1. Check the species and the system. Every cited finding here comes from cells or rats.
2. Check the endpoint. Cytokine concentrations and enzyme activity are markers, not symptoms or diagnoses.
3. Check independence. Much of the short-peptide literature originates from a small number of affiliated groups and journals, and independent replication is limited.
4. Check the language. A paper reporting "protection" in a defined model is describing that model, not a general claim about human health.

In short, pinealon is best understood as a defined research term with a small, mostly preclinical evidence base. The literature describes what happened in specific experiments; it does not establish clinical effects in people, and nothing on this page should be read as guidance about personal use.

References

• Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes (Rejuvenation Research, 2011)
• Pinealon protects the rat offspring from prenatal hyperhomocysteinemia (International Journal of Clinical and Experimental Medicine, 2012)
• Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon (Advances in Gerontology, 2014)
• Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia (Advances in Gerontology, 2015)